



Dear Healthcare Professional,

We would like to inform you regarding an update to the patient information leaflet for **Vermox 500 mg tablet**.

As a result of the change in the reference label of this product from Switzerland to Italy, the following statement have now been removed from the patient information leaflet in Jordan:

“Inform your doctor if you are taking drugs like carbamazepine and/or phenytoin (to treat epilepsy).”

This is further supported by cumulative review and analysis of available scientific data, which concluded that there is insufficient evidence of drug-drug interaction between carbamazepine and/or phenytoin with mebendazole.

This letter is being sent upon alignment with Jordan Food and Drug Administration (JFDA).

For your kind information.

Call for reporting
Jordan Food and Drug Administration (JFDA)

Email: jpc@jfda.jo
Website: <http://www.jfda.jo/>

Electronic reporting form: <https://primaryreporting.who-umc.org/JO>

Tel: +962-6-5632000

QR Code



Company contact points

Janssen scientific office:

Telephone: +2 21291100 Mobile: +2 01000629760

E-mail: JACEG-PV@its.jnj.com **Adverse events related to Vermox should be reported to**

Janssen PV department

Email: JACEG-PV@its.jnj.com